Emerald Advisers LLC Has $306,000 Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Emerald Advisers LLC trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 21.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,812 shares of the medical equipment provider’s stock after selling 1,062 shares during the quarter. Emerald Advisers LLC’s holdings in Lantheus were worth $306,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 208 shares during the last quarter. UMB Bank n.a. lifted its holdings in Lantheus by 161.4% during the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 247 shares during the period. Principal Securities Inc. bought a new stake in shares of Lantheus in the 4th quarter valued at about $28,000. Fidelis Capital Partners LLC acquired a new position in shares of Lantheus in the first quarter worth approximately $34,000. Finally, FinTrust Capital Advisors LLC increased its position in Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 232 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LNTH. B. Riley boosted their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. JMP Securities dropped their target price on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a report on Thursday, August 1st. Redburn Atlantic began coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target for the company. Leerink Partners boosted their price objective on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Finally, Truist Financial decreased their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and an average price target of $126.00.

Lantheus Stock Down 3.2 %

Lantheus stock opened at $101.98 on Monday. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. The firm’s fifty day moving average price is $102.61 and its two-hundred day moving average price is $81.60. The firm has a market capitalization of $7.08 billion, a price-to-earnings ratio of 15.57 and a beta of 0.50. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. Lantheus’s revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.40 EPS. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total transaction of $27,201.57. Following the transaction, the chief accounting officer now directly owns 62,557 shares in the company, valued at approximately $4,990,171.89. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CAO Andrea Sabens sold 341 shares of the stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the sale, the chief accounting officer now owns 62,557 shares in the company, valued at $4,990,171.89. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gary J. Pruden sold 12,530 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the transaction, the director now owns 11,978 shares in the company, valued at $1,138,389.12. The disclosure for this sale can be found here. Insiders have sold a total of 41,193 shares of company stock valued at $3,949,202 over the last 90 days. Insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.